Treatment of oesophageal cancer – Stressing the patient perspective
- 1 October 2017
- journal article
- editorial
- Published by Elsevier BV in European Journal of Cancer
- Vol. 84, 360-362
- https://doi.org/10.1016/j.ejca.2017.08.021
Abstract
No abstract availableThis publication has 12 references indexed in Scilit:
- Health-related quality of life results from the PRODIGE 5/ACCORD 17 randomised trial of FOLFOX versus fluorouracil–cisplatin regimen in oesophageal cancerEuropean Journal of Cancer, 2017
- Oesophageal cancerNature Reviews Disease Primers, 2017
- Nivolumab treatment for oesophageal squamous-cell carcinoma: an open-label, multicentre, phase 2 trialThe Lancet Oncology, 2017
- Integrated genomic characterization of oesophageal carcinomaNature, 2017
- Oesophageal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upAnnals of Oncology, 2016
- Definitive chemoradiotherapy with FOLFOX versus fluorouracil and cisplatin in patients with oesophageal cancer (PRODIGE5/ACCORD17): final results of a randomised, phase 2/3 trialThe Lancet Oncology, 2014
- A comparison of carboplatin and paclitaxel with cisplatinum and 5-fluorouracil in definitive chemoradiation in esophageal cancer patientsAnnals of Oncology, 2014
- Preoperative Chemoradiotherapy for Esophageal or Junctional CancerThe New England Journal of Medicine, 2012
- Six-month postoperative quality of life predicts long-term survival after oesophageal cancer surgeryEuropean Journal of Cancer, 2011
- Quality of life as a survival predictor for esophageal squamous cell carcinoma treated with radiotherapyInternational Journal of Radiation Oncology*Biology*Physics, 2004